Does sonelokimab finally justify MoonLake’s best-in-class hidradenitis suppurativa claim?
Sonelokimab delivered deeper one-year hidradenitis suppurativa responses, but MoonLake must convert cross-trial advantages into regulatory approval and commercial differentiation.